deferoxamine has been researched along with salen in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akimoto, T; Aoyama, H; Eguchi, H; Fujita, T; Fukumura, H; Hoshino, Y; Ishikawa, Y; Kim, JH; Nakakaji, R; Narikawa, M; Ohtake, M; Okumura, S; Sato, I; Sato, M; Taguri, M; Tanaka, R; Umemura, M; Yokoyama, U | 1 |
1 other study(ies) available for deferoxamine and salen
| Article | Year |
|---|---|
The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Topics: Acute Kidney Injury; Animals; Antidotes; Antineoplastic Agents; Chelating Agents; Chemical and Drug Induced Liver Injury; Deferoxamine; Dose-Response Relationship, Drug; Ethylenediamines; Humans; Iron; Iron Chelating Agents; Rabbits; Reactive Oxygen Species; Tumor Cells, Cultured | 2017 |